Stock Analysis on Net
Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Johnson & Johnson, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Turnover Ratios
Inventory turnover 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Receivables turnover 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Payables turnover 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Working capital turnover 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Average No. Days
Average inventory processing period 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Add: Average receivable collection period 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Operating cycle 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Less: Average payables payment period 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Cash conversion cycle 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


Operational efficiency has demonstrated a consistent decline over the observed period, characterized by an overall lengthening of the cash conversion cycle and a gradual reduction in asset turnover rates.

Inventory and Receivables Management
Inventory turnover exhibits a steady downward trajectory, decreasing from 2.77 in April 2022 to 2.08 by June 2026. This trend is mirrored in the average inventory processing period, which expanded from 132 days to 176 days, indicating a slowing rate of inventory movement. Simultaneously, the receivables turnover has trended downward from 6.08 to 5.14, causing the average receivable collection period to extend from 60 days to 71 days. The cumulative effect of these two metrics is an expansion of the total operating cycle from 192 days to 247 days.
Payables and Cash Conversion Cycle
The average payables payment period has remained volatile, fluctuating between a low of 107 days and a high of 145 days without a consistent linear trend. While payables management provides some offset to the operating cycle, it has been insufficient to counteract the slowdown in inventory and receivable turnover. As a result, the cash conversion cycle has increased significantly from 80 days in April 2022 to 140 days by June 2026, suggesting that liquidity is increasingly tied up in operational activities.
Working Capital Utilization
Working capital turnover exhibits extreme instability, marked by sporadic and significant spikes, most notably reaching 284.99 in June 2025 and 66.14 in December 2025. These erratic fluctuations suggest substantial volatility in the net working capital position relative to sales, contrasting with the more gradual and predictable declines observed in the individual turnover ratios.

AI Ask an analyst for more


Turnover Ratios


Average No. Days



Inventory Turnover

Johnson & Johnson, inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,051 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Inventories 15,144 14,583 14,191 14,146 13,412 12,659 12,444 12,603 12,169 11,383 11,181 11,198 12,888 12,809 12,483 11,675 11,437 10,990
Short-term Activity Ratio
Inventory turnover1 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Merck & Co. Inc. 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Inventory turnover = (Cost of products soldQ2 2026 + Cost of products soldQ1 2026 + Cost of products soldQ4 2025 + Cost of products soldQ3 2025) ÷ Inventories
= (8,051 + 8,106 + 7,968 + 7,303) ÷ 15,144 = 2.08

2 Click competitor name to see calculations.


A consistent downward trajectory is observed in the inventory turnover ratio from April 2022 through June 2026. The ratio decreased from a high of 2.77 to 2.08, indicating a reduction in the efficiency of inventory conversion and a slower rate of stock movement over the analyzed period.

Cost of Products Sold Analysis
Expenditures related to the cost of products sold exhibited initial volatility, peaking at 7,919 million USD in July 2022 before declining to a low of 6,462 million USD by July 2023. Following this trough, a steady recovery is observed, with costs rising to 8,051 million USD by June 2026. This suggests a gradual increase in production volume or rising input costs over the latter half of the period.
Inventory Level Trends
Inventory holdings demonstrate a general upward trend, rising from 10,990 million USD in April 2022 to 15,144 million USD by June 2026. Although a temporary contraction occurred in late 2023, reaching a low of 11,181 million USD in December, a sustained accumulation of stock began in early 2024. The growth in inventory assets has significantly outpaced the growth in the cost of products sold during the final two years of the period.
Inventory Turnover Ratio Interpretation
The turnover ratio experienced a persistent decline, falling below the 2.30 threshold in early 2023 and continuing to erode to a final value of 2.08. This compression indicates that goods are remaining in inventory for longer durations. The divergence between rising inventory levels and more modest growth in the cost of products sold identifies the primary driver of this efficiency loss, suggesting potential overstocking or a shift in demand dynamics.

AI Ask an analyst for more



Receivables Turnover

Johnson & Johnson, receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers 25,310 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Accounts receivable, trade, less allowances 19,046 17,721 17,178 17,611 17,846 16,020 14,842 16,174 15,794 14,946 14,873 14,798 16,777 16,350 16,160 15,890 16,139 15,594
Short-term Activity Ratio
Receivables turnover1 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Merck & Co. Inc. 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Receivables turnover = (Sales to customersQ2 2026 + Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025) ÷ Accounts receivable, trade, less allowances
= (25,310 + 24,062 + 24,564 + 23,993) ÷ 19,046 = 5.14

2 Click competitor name to see calculations.


The analyzed period is characterized by a gradual decline in receivables turnover efficiency, suggesting a lengthening of the average collection cycle. While sales volumes showed a recovery and eventual growth trend toward the end of the period, the balance of trade receivables increased at a rate that outpaced revenue growth, resulting in a compressed turnover ratio.

Sales Trends
Sales to customers experienced a period of volatility, with a notable dip throughout 2023, reaching a low of 20,894 million USD in April 2023. Following this trough, a consistent upward trajectory was observed from 2024 through June 2026, where sales peaked at 25,310 million USD.
Accounts Receivable Patterns
Trade receivables remained relatively stable between 14,798 million USD and 16,777 million USD from April 2022 through December 2023. However, starting in early 2025, a significant increase in outstanding receivables occurred, with the balance rising to 19,046 million USD by June 2026. This increase indicates a higher accumulation of credit extended to customers relative to previous years.
Receivables Turnover Efficiency
The receivables turnover ratio exhibited a general downward trend, starting at 6.08 in April 2022 and ending at 5.14 in June 2026. A period of relative stability was maintained around the 5.7 to 5.9 range through 2023, but the ratio experienced a more pronounced decline starting in 2024, hitting a period low of 5.08 in June 2025. The consistent decrease in this ratio reflects a reduction in the frequency with which the company collects its average receivables balance during each quarter.

AI Ask an analyst for more



Payables Turnover

Johnson & Johnson, payables turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,051 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Accounts payable 9,223 10,460 11,991 9,625 9,464 9,545 10,311 8,954 8,848 8,174 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309
Short-term Activity Ratio
Payables turnover1 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Merck & Co. Inc. 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Payables turnover = (Cost of products soldQ2 2026 + Cost of products soldQ1 2026 + Cost of products soldQ4 2025 + Cost of products soldQ3 2025) ÷ Accounts payable
= (8,051 + 8,106 + 7,968 + 7,303) ÷ 9,223 = 3.41

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates a period of moderate volatility in payables management, characterized by cyclical fluctuations in the payables turnover ratio. The ratio generally oscillates between a low of 2.52 and a high of 3.41, reflecting varying efficiencies in the settlement of supplier obligations relative to the cost of products sold.

Cost of Products Sold Trends
Expenditures for products sold demonstrated a fluctuating trajectory, beginning at 7,598 million USD in April 2022 and reaching a trough of 6,462 million USD by July 2023. Following this decline, a consistent upward trend is observed from December 2023 through March 2026, where costs peaked at 8,106 million USD before slightly moderating to 8,051 million USD by June 2026.
Accounts Payable Dynamics
Accounts payable balances exhibit significant variance, with recurring peaks occurring at the end of calendar years. Notable spikes are observed in December 2022 (11,703 million USD) and December 2025 (11,991 million USD). Conversely, the lowest levels of liabilities were recorded in October 2023 (8,355 million USD) and March 2024 (8,174 million USD), suggesting periods of aggressive settlement or reduced procurement volumes.
Payables Turnover Analysis
The payables turnover ratio shows a distinct pattern of year-end deceleration. A recurring decline in the ratio is evident every December, with the lowest values recorded in December 2025 (2.52) and December 2024 (2.66). This indicates a trend of extending payment terms or accumulating larger payables balances at the close of the fiscal year. Efficiency peaks are observed more frequently in the first and third quarters, reaching a maximum of 3.41 in June 2026, which suggests a more rapid conversion of payables into costs of products sold during these periods.

Overall, the relationship between the cost of products sold and accounts payable suggests a strategic or seasonal approach to liquidity management. The inverse correlation between the spikes in accounts payable and the dips in the turnover ratio confirms that the company's short-term operating efficiency is heavily influenced by year-end liability accumulation.

AI Ask an analyst for more



Working Capital Turnover

Johnson & Johnson, working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets 59,774 59,173 55,624 54,611 54,498 71,551 55,893 53,249 57,817 57,002 53,495 53,703 60,567 64,388 55,294 65,236 63,847 60,424
Less: Current liabilities 54,895 57,716 54,126 50,869 54,180 56,903 50,321 51,759 53,933 48,725 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390
Working capital 4,879 1,457 1,498 3,742 318 14,648 5,572 1,490 3,884 8,277 7,213 9,333 6,397 4,015 (508) 19,693 19,026 17,034
 
Sales to customers 25,310 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Short-term Activity Ratio
Working capital turnover1 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Merck & Co. Inc. 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Working capital turnover = (Sales to customersQ2 2026 + Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025) ÷ Working capital
= (25,310 + 24,062 + 24,564 + 23,993) ÷ 4,879 = 20.07

2 Click competitor name to see calculations.


The analysis of operating activity reveals a significant divergence between the stability of revenue generation and the volatility of working capital management over the observed period. While sales to customers remained relatively consistent, working capital experienced extreme fluctuations, leading to erratic swings in the working capital turnover ratio.

Working Capital Trends
Working capital exhibited substantial volatility, characterized by sharp contractions and expansions. Initial levels remained high through much of 2022, before plummeting to a negative value of -508 million by December 31, 2022. Subsequent periods showed inconsistent recovery, with a peak of 14,648 million in December 2024, followed by a rapid decline to 318 million by June 2025. This pattern suggests aggressive adjustments in short-term asset and liability management.
Sales Performance
Revenue from sales to customers demonstrated remarkable stability, generally fluctuating within a narrow band between 20,894 million and 25,310 million. The absence of significant volatility in sales indicates that the dramatic changes observed in the turnover ratio are driven entirely by balance sheet fluctuations rather than operational growth or decline in market demand.
Working Capital Turnover Interpretation
The working capital turnover ratio displayed extreme variance due to the diminishing denominator of working capital. In early 2022, the ratio was stable between 4.88 and 5.57. However, as working capital decreased, the ratio spiked mathematically, reaching an anomalous peak of 284.99 in June 2025. Such high ratios typically indicate that the company is operating with minimal net working capital, which may increase liquidity risk despite the appearance of high efficiency. Toward the end of the period, the ratio stabilized at a higher plateau, ranging between 20.07 and 66.14, reflecting a sustained shift toward a leaner working capital structure compared to 2022 levels.

AI Ask an analyst for more



Average Inventory Processing Period

Johnson & Johnson, average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Inventory turnover 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Short-term Activity Ratio (no. days)
Average inventory processing period1 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Merck & Co. Inc. 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.08 = 176

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a consistent decline in inventory management efficiency over the period from April 2022 to June 2026. There is a clear inverse correlation between the inventory turnover ratio and the average inventory processing period, characterized by a steady increase in the time required to convert inventory into sales.

Inventory Turnover Trend
The inventory turnover ratio exhibits a long-term downward trajectory, moving from a high of 2.77 in April 2022 to a low of 2.08 by June 2026. Although temporary improvements are observed—specifically in October 2023 (2.46) and December 2024 (2.21)—these spikes were short-lived and failed to reverse the broader trend of slowing inventory replacement.
Average Inventory Processing Period Analysis
The average inventory processing period increased from 132 days in April 2022 to 176 days by June 2026. A notable acceleration in this period occurred between December 2022 (147 days) and July 2023 (164 days). From 2024 onwards, the processing period remained elevated, fluctuating within a range of 163 to 176 days, signaling a structural shift in inventory holding durations.
Operational Implications
The expansion of the processing period by 44 days over the analyzed timeframe suggests a reduction in operational velocity. The data indicates that inventory is remaining on hand longer, which may be attributed to increased safety stock levels, a slowdown in demand, or inefficiencies in the supply chain. This trend reflects a decrease in short-term asset liquidity as a larger portion of capital remains tied up in inventory for extended durations.

AI Ask an analyst for more



Average Receivable Collection Period

Johnson & Johnson, average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Receivables turnover 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Short-term Activity Ratio (no. days)
Average receivable collection period1 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Merck & Co. Inc. 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.14 = 71

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates a gradual decline in the efficiency of receivables management between April 2022 and June 2026. A consistent inverse relationship is observed between the receivables turnover ratio and the average collection period, characterized by a downward trend in turnover and a corresponding increase in the number of days required to collect outstanding payments.

Receivables Turnover Trend
The receivables turnover ratio experienced a steady contraction over the observed period. Starting at a peak of 6.08 in April 2022, the ratio generally trended lower, reaching its lowest point of 5.08 in June 2025. While some periodic recoveries occurred—most notably a rise to 5.98 in December 2024—the ratio concluded the period at 5.14 in June 2026, representing a clear reduction in the frequency with which accounts receivable are converted into cash.
Average Receivable Collection Period Analysis
The time required to collect receivables shifted from a baseline of 60 days in early 2022 to a high of 72 days by June 2025. The collection period remained relatively stable around 60 to 62 days throughout 2022 but began to exhibit upward pressure in 2023 and 2024. Despite a temporary improvement to 61 days in December 2024, the period extended significantly thereafter, ending at 71 days in June 2026.
Operational Insights and Volatility
The data suggests a slowing of the cash conversion cycle related to receivables. The transition from a 60-day collection average to a 71-day average indicates that capital is tied up in receivables for approximately 11 days longer than at the start of the analysis. The most significant period of deterioration occurred between December 2024 and June 2025, where the collection period jumped from 61 to 72 days, signaling a potential shift in credit terms or a decrease in customer payment velocity during that window.

AI Ask an analyst for more



Operating Cycle

Johnson & Johnson, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Short-term Activity Ratio
Operating cycle1 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Merck & Co. Inc. 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 176 + 71 = 247

2 Click competitor name to see calculations.


The operating cycle exhibits a sustained upward trajectory over the analyzed period, expanding from 192 days in April 2022 to 247 days by June 2026. This progression indicates a significant lengthening of the time required to convert initial inventory investments into cash, signaling a decrease in short-term operational efficiency regarding asset turnover.

Average Inventory Processing Period
A consistent increase is observed in the duration of inventory processing, which rose from 132 days at the start of the period to 176 days by the end. A period of rapid escalation occurred between December 2022 and July 2023, where the period grew from 147 to 164 days. The trend remained generally positive, with a peak of 176 days reached in September 2025 and maintained through June 2026, suggesting a systemic slowing in inventory turnover.
Average Receivable Collection Period
The collection period for receivables shows relative stability compared to inventory processing but still reflects a marginal upward trend, increasing from 60 days to 71 days. Fluctuations are present, with a notable peak of 72 days in June 2025 and a brief dip to 61 days in December 2024. Overall, the increasing trend suggests a slight deceleration in the efficiency of credit collection processes.
Operating Cycle Synthesis
The expansion of the overall operating cycle is primarily driven by the growth in the average inventory processing period. While the receivable collection period contributed to the increase, the inventory component represents the dominant factor in the shift from a 192-day cycle to a 247-day cycle. The most pronounced expansions in the cycle occurred during mid-2023 and mid-2025, correlating with peak values in both inventory and receivable metrics.

AI Ask an analyst for more



Average Payables Payment Period

Johnson & Johnson, average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Payables turnover 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Short-term Activity Ratio (no. days)
Average payables payment period1 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Merck & Co. Inc. 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.41 = 107

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates a cyclical pattern in the management of accounts payable, characterized by recurring fluctuations in both the payables turnover ratio and the average payables payment period.

Average Payables Payment Period Trends
A consistent seasonal trend is observed, with payment durations peaking during the final quarter of each calendar year. Specifically, the period extended to 137 days in December 2022, 132 days in December 2023, 137 days in December 2024, and reached a peak of 145 days in December 2025. These peaks are typically followed by a contraction in the payment period during the subsequent quarters. The most recent data point for June 28, 2026, shows a reduction to 107 days, the lowest value in the analyzed period.
Payables Turnover Ratio Analysis
The turnover ratio exhibits an inverse correlation with the payment period, oscillating between a minimum of 2.52 in December 2025 and a maximum of 3.41 in June 2026. The ratio generally declines toward the end of the year, indicating a slower frequency of supplier payments and a corresponding increase in the average time taken to settle obligations.
Operational Liquidity Insights
The recurring year-end extension of the payment period suggests a strategic management of working capital or the utilization of favorable supplier credit terms to optimize cash flow at the close of the fiscal year. The transition from December 2025 to June 2026 represents the most significant shift in the series, moving from the longest payment duration (145 days) to the shortest (107 days), which corresponds with the highest recorded turnover ratio of 3.41.

AI Ask an analyst for more



Cash Conversion Cycle

Johnson & Johnson, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Average payables payment period 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Short-term Activity Ratio
Cash conversion cycle1 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Merck & Co. Inc. 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 176 + 71107 = 140

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a pronounced upward trend over the analyzed period, indicating a lengthening of the time required to convert operational inputs into cash flows. Starting at 80 days in April 2022, the cycle experienced several fluctuations before reaching a peak of 140 days by June 2026. This expansion suggests a decline in overall working capital efficiency.

Average Inventory Processing Period
A consistent and significant increase in the inventory processing period is observed. The duration rose from 132 days in April 2022 to 176 days by June 2026. This steady climb indicates a slowing of inventory turnover, which serves as the primary driver for the expansion of the overall cash conversion cycle.
Average Receivable Collection Period
The period for collecting receivables remained relatively stable compared to inventory, though a gradual upward drift is evident. Collection times moved from 60 days in early 2022 to 71 days by June 2026. While less volatile than other metrics, the peak of 72 days in June 2025 highlights a slight degradation in the efficiency of credit and collection processes.
Average Payables Payment Period
The payables payment period demonstrates significant volatility and apparent seasonality. Periodic spikes are observed at year-end, reaching 137 days in December 2022 and December 2024, and a peak of 145 days in December 2025. These peaks typically provided temporary relief to the cash conversion cycle, though the period contracted to 107 days by June 2026, further contributing to the rise in the total cycle duration.
Cash Conversion Cycle Synthesis
The deterioration of the cash conversion cycle is primarily attributed to the substantial increase in inventory holding times, which was not sufficiently offset by the management of payables. The cycle remained below 100 days through late 2022 but transitioned to a higher baseline starting in 2023. The final surge to 140 days in June 2026 coincides with a simultaneous peak in inventory processing and a sharp reduction in the payables payment period.

AI Ask an analyst for more